Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

Biomea's Icovamenib Shows Durable C-Peptide Improvement in Phase 2 T1D Trial

Biomea Fusion announced positive 52-week results from its Phase 2 COVALENT-112 trial of icovamenib in type 1 diabetes (T1D). In patients diagnosed within 0-3 years (n=5) receiving 200 mg, mean C-peptide AUC increased by 52% at Week 12 (p < 0.001). This improvement showed durability, with C-peptide AUC largely preserved through Week 52, declining only ~7% from baseline after just 12 weeks of dosing. C-peptide preservation was also observed in patients with longer-standing disease (3-15 years). Icovamenib was generally well tolerated, demonstrating a favorable safety profile. These findings support menin targeting as a promising approach for T1D.

• Icovamenib 200 mg once daily for 12 weeks led to a 52% increase in mean C-peptide AUC at Week 12 (p < 0.001) in patients diagnosed with T1D within 0-3 years (n=5). This magnitude of improvement in endogenous insulin secretion is considered rare in published T1D studies, indicating a substantial potential benefit for newly diagnosed patients. A clear dose-response was observed, with the 200 mg dose showing greater activity than 100 mg.
• The positive effects on C-peptide were durable, with mean C-peptide AUC largely preserved through Week 52, showing only approximately a 7% decline from baseline, despite only 12 weeks of active treatment. This persistence is crucial given the typical progressive decline in C-peptide in Stage 3 T1D. Icovamenib was also generally well tolerated throughout the 52-week observation period, with no new or unexpected safety signals identified, supporting its safety profile.
• Beyond early-stage T1D, C-peptide levels were generally preserved through Week 52 in patients with longer-standing disease (3-15 years since diagnosis), suggesting potential benefits across a wider patient population. Based on these encouraging data, Biomea plans to initiate a new Phase 2 trial in the second half of this year, exploring extended dosing (up to 6 or 12 months) at 200 mg and the potential for combination with an immunosuppressive agent.

The Persistent Challenges in Type 1 Diabetes Management

Despite decades of scientific progress in diabetes care, type 1 diabetes management continues to face fundamental limitations that impact patient outcomes and quality of life. Current treatment approaches remain unable to achieve normal glycemic control consistently, particularly over the long term, and carry persistent risks of serious complications. The absence of a cure means patients face lifelong insulin dependency with the prospect of diminished health and earlier mortality compared to the general population.

• Inadequate glycemic control: Even with improved insulin therapies and technological advances, achieving and maintaining normal blood glucose levels remains difficult, especially long-term, with disease control remaining suboptimal despite modern insulin delivery systems.

• Persistent hypoglycemia risk: Current insulin therapies continue to carry associated risks of hypoglycemia and end-organ diabetic complications, creating a complex balancing act between glucose control and safety.

• Limited therapeutic options: More than 100 years after insulin's discovery, there are no oral medications approved for type 1 diabetes in the United States, and no approved medications effectively target β-cell loss or islet dysfunction—major underlying causes of the disease.

• Immunotherapy limitations: The FDA-approved immunotherapy teplizumab has a limited window of opportunity for implementation, approved only for stage 2 type 1 diabetes, with challenges in treatment accessibility and cost-effectiveness requiring further research.

• Islet transplantation constraints: Cell-based therapies involving functional β-cell transplantation show limited success due to restricted availability of human islets from cadaveric pancreata and the need for toxic immunosuppressive regimens to prevent graft failure.

• Beta cell regeneration obstacles: While regeneration from stem cells may overcome islet source limitations, the persistent hostile autoimmune response threatens to destroy regenerated beta cells, limiting therapeutic potential.

• Adjunctive therapy trade-offs: Although adjunctive therapies like SGLT inhibitors and GLP-1 receptor agonists may improve glycemic control and reduce insulin requirements, they increase risks of diabetic ketoacidosis, gastrointestinal side effects, and hypoglycemia.

• Global accessibility barriers: People in under-resourced regions struggle to obtain essential diabetes management necessities including insulin, syringes, and blood glucose monitoring equipment, creating fundamental disparities in care.

COVALENT-112: Design, Endpoints, and Positive 52-Week Outcomes

The MELD-ATG trial represents a landmark investigation in Type 1 diabetes intervention, employing a sophisticated adaptive dose-ranging design to evaluate antithymocyte globulin (ATG) in recently diagnosed patients. This phase 2 study, conducted across 14 centers in eight countries, utilized an innovative multi-cohort approach with stratified randomization to assess optimal dosing strategies. The trial's primary focus on C-peptide preservation as measured by mixed-meal tolerance testing reflects the field's emphasis on beta-cell function preservation in early-stage disease.

Icovamenib's Broader Potential: Targeting Menin Across Diabetes

Icovamenib (BMF-219) is being investigated across several hematological malignancies, representing a significant expansion beyond its diabetes applications. The drug is currently in clinical trials for acute myeloid leukemia (AML) with specific genetic alterations, including KMT2A rearrangements and NPM1 mutations. Additionally, the compound is being evaluated for leukemias characterized by NUP98 rearrangements and UBTF tandem duplications, as well as relapsed/refractory acute leukemia cases.

The therapeutic rationale for these oncology indications centers on icovamenib's mechanism as a menin inhibitor, which disrupts the menin-KMT2A protein-protein interaction. This approach specifically targets HOX-dependent acute leukemias that demonstrate epigenetic dependency on the menin-KMT2A axis. The genetic alterations being studied, particularly KMT2A rearrangements and NPM1 mutations, are known to drive leukemogenesis through dysregulated gene expression programs that can be therapeutically addressed through menin inhibition.

These oncology trials represent a strategic application of icovamenib's menin-targeting mechanism across different disease contexts, leveraging the protein's role in both metabolic regulation and hematopoietic malignancies. The focus on genetically defined patient populations suggests a precision medicine approach, where biomarker-driven patient selection may optimize therapeutic outcomes across these distinct but mechanistically related indications.

Menin Inhibition: A New Horizon for Type 1 Diabetes

The recent positive 52-week results for icovamenib in type 1 diabetes (T1D) mark a potentially transformative moment for patients and the broader pharmaceutical landscape. While menin inhibitors have garnered significant attention and regulatory approval in acute leukemias, these new data suggest a compelling expansion of their therapeutic utility into autoimmune diseases. The core insight lies in menin's role in suppressing pancreatic β-cell proliferation; by inhibiting menin, icovamenib appears to reverse this suppression, leading to the preservation of endogenous insulin production, as evidenced by sustained C-peptide levels. This is a profound shift from current T1D management, which primarily focuses on replacing insulin.

For Biomea Fusion, this opens a vast new market opportunity, positioning icovamenib as a potential disease-modifying agent rather than just a symptom manager. The durability of C-peptide preservation observed over 52 weeks, following a relatively short dosing period, is particularly encouraging, hinting at a sustained benefit that could significantly improve patient outcomes and quality of life.

However, the path forward is not without its considerations. The current data, while promising, stems from a very small patient cohort, underscoring the critical need for larger, randomized controlled trials to confirm both efficacy and long-term safety. Furthermore, the experience with menin inhibitors in oncology has highlighted potential adverse events such as differentiation syndrome and QTc prolongation. While icovamenib was generally well-tolerated in this T1D study, vigilance for these and other potential toxicities will be paramount in a chronic treatment setting. The mechanism of inducing β-cell proliferation, while therapeutic, also warrants careful long-term monitoring to ensure no unforeseen consequences arise from sustained cellular activity. The successful translation of this mechanism into a safe and effective T1D therapy would not only validate a novel approach but also solidify the menin pathway as a versatile and impactful target across diverse disease areas.